MedImmune acquires 100% stake in Amplimmune - MarketLine Financial Deals

MedImmune acquires 100% stake in Amplimmune

MedImmune acquires 100% stake in Amplimmune - MarketLine Financial Deals
MedImmune acquires 100% stake in Amplimmune
Published Oct 04, 2013
3 pages — Published Oct 04, 2013
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

MedImmune LLC, the biologics research and development arm of AstraZeneca PLC, has acquired 100% stake in Amplimmune.

  
Source:
Document ID
MA141601_130828
Country
Country
Ticker
AZN=GB
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "MedImmune acquires 100% stake in Amplimmune" Oct 04, 2013. Alacra Store. Dec 04, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/MedImmune-acquires-100-stake-in-Amplimmune-2052-97050>
  
APA:
MarketLine Financial Deals. (2013). MedImmune acquires 100% stake in Amplimmune Oct 04, 2013. New York, NY: Alacra Store. Retrieved Dec 04, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/MedImmune-acquires-100-stake-in-Amplimmune-2052-97050>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.